Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeladys: Tetrabenazine for Tardive Dyskinesia
NCT01543321Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- May 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tardive dyskinesia (TD) comparing Tetrabenazine group with Placebo group (2 arms). Primary endpoint: Extrapyramidal Symptoms Rating Scale at 10 weeks. Started May 2012; status: completed.
02
Drugs
tetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT01543321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543321.